uploads///Chart  Oncology

Eli Lilly & Co.’s Oncology Franchise



Oncology franchise

Eli Lilly and Co.’s (LLY) Human Pharmaceuticals segment includes its Oncology franchise. Key drugs in this segment include Alimta, Erbitux, Cyramza, and Portrazza.

Article continues below advertisement


Alimta is a chemotherapy drug used in the treatment of patients with advanced non-small cell lung cancer. Alimta’s sales fell ~14% to $541.6 million during 4Q16, compared to $627.2 million for 4Q15. This included a 5% decrease in the US market and an ~21% decrease in international sales.

Alimta lost its market share to competition from other immuno-oncology products in the US markets. Its international sales were impacted by the continuous uptake of the generic version, as well as lower average prices. Alimta has a competitor drug from Allergan (AGN).


Erbitux is a drug used in the treatment of metastatic colorectal cancer, as well as head and neck cancer. Erbitux’s sales fell 13% to $153.7 million in 4Q16, compared to ~$176.2 million in 4Q15. Eli Lilly took back the commercialization rights for Erbitux in North America from Bristol-Myers Squibb (BMY) on October 1, 2015.

Erbitux’s US revenues fell due to initial stocking and competition from other immune-oncology drugs. Erbitux competes with Roche’s (RHHBY) Avastin and Amgen’s (AMGN) Vectibix.

Other drugs

LLY’s Oncology franchise also includes Cyramza and Portrazza. Cyramza’s revenues rose 51% during 4Q16 following strong uptake in Japan and its launch in the European markets. Portrazza reported revenues of ~$4 million in 4Q16.

For broad-based industry exposure, investors can consider the PowerShares Dynamic Large Growth ETF (PWB) which invests 3.7% of its portfolio in Eli Lilly (LLY).


More From Market Realist